{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-039221","form_type":"8-K","ticker":"XWEL","cik":"0001410428","company_name":"XWELL, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.813167+00:00","generated_at":"2026-06-17T09:06:47.761572+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"XWELL to file late 10-K due to impairment review; preliminary FY2022 revenue ~$56M","bullets":["Plans to file Form 12b-25 for 15-day extension to assess non-cash impairment charge; 10-K expected by April 17, 2023.","Preliminary FY2022 total revenue ~$56M: XpresSpa/Treat $15M, XpresCheck $32M, bio-surveillance $7M, HyperPointe $2M.","Gross profit margin declined to ~22% from ~44% in 2021 due to lower testing volumes.","G&A expenses ~$31M; second-half 2022 G&A ~$4M lower than first half reflecting cost savings.","Cash and equivalents ~$42M; opened 5 XpresSpa locations in Istanbul, new spa at Philadelphia in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-039221","json":"https://secwatch.observer/filing/0001104659-23-039221.json","markdown":"https://secwatch.observer/filing/0001104659-23-039221.md","text":"https://secwatch.observer/filing/0001104659-23-039221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410428/000110465923039221/0001104659-23-039221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410428/000110465923039221/tm2311046d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:06:47.761572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7abf9367cedb275d036da12929b55552ee6e9c4","claim":"XWELL, Inc. reported fiscal year ended December 31, 2022 results: revenue to total approximately $56 million.","evidence_excerpt":"The Company also announced preliminary unaudited financial results for the fiscal year ended December 31, 2022. Selected Preliminary Fiscal Year 2022 Financial Update · Fiscal year 2022 total revenue is projected to total approximately $56 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410428/000110465923039221/0001104659-23-039221-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Revenue","value":"to total approximately $56 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}